Peptide · Fact sheet

MOTS-c

Also known as MOTS-c peptide · mitochondrial ORF of 12S rRNA type-c

MOTS-c is an experimental mitochondrial-derived peptide studied for metabolism, exercise adaptation, and aging biology. It is not FDA approved, and FDA reports no identified human exposure data for drug products containing MOTS-c.

Preclinical researchMostly animal or lab research

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and produced as part of cellular stress and metabolic signaling.

Studies measuring natural MOTS-c levels in people are not treatment trials, and a synthetic analog such as CB4211 is not interchangeable with native MOTS-c.

Benefits & claims

Animal studies report effects on insulin sensitivity, metabolic stress, physical capacity, and age-related decline.

Those findings have fueled 'exercise mimetic' and longevity claims that go far beyond direct human intervention evidence.

What the evidence supports

  • Animal studies report improved insulin sensitivity and physical capacity under selected experimental conditions.
  • Human observational work shows associations with exercise and muscle measures, but association does not prove that administering MOTS-c produces a benefit.
Research areas
  • Insulin sensitivity and metabolic regulation in animal models
  • Exercise adaptation and physical capacity
  • Age-related metabolic decline
  • Muscle stress and mitochondrial signaling
  • Metabolic disease and fatty-liver research
  • Exercise and muscle-function biology
  • Healthy-aging mechanisms

Dosage & frequency

No established human regimen

MOTS-c evidence does not establish a human injection dose for metabolic health or exercise performance.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • A measured endogenous peptide level is not a treatment exposure.
  • Studies of related investigational analogs cannot be assumed to apply to native MOTS-c.

Interactions & precautions

  • Human interaction data are unestablished for native MOTS-c; findings for endogenous levels or related analogs cannot establish combination safety.

What is still unresolved

  • Human dosing, pharmacokinetics, clinical efficacy, repeated-use safety, and interactions remain unestablished.

Side effects & risks

  • FDA identifies potential immune reactions and complexities involving peptide impurities and active-ingredient characterization.
  • There is no adequate human treatment dataset from which to estimate common, uncommon, or long-term harms.
  • Unapproved products add identity, purity, sterility, strength, and labeling risks.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

Most treatment claims come from cells and animals. Human studies largely measure naturally circulating MOTS-c or response to exercise rather than test MOTS-c as a therapy.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Energy improved after several different exposures

A commenter reported little energy initially and more energy later, after a sequence involving SS-31, MOTS-c and NAD+.

Reported use in this account

Product
Product described as MOTS-c
Amount
5 mg initially; later 3 mg, as reported
Frequency
Daily at the later 3 mg exposure; the earlier “5/2” notation is not expanded
Route
Not specified clearly
Duration
Two weeks initially and another two weeks later

Other exposures described: SS-31 before and between MOTS-c exposures; NAD+ added later

Multiple products and time effects prevent attribution to MOTS-c. The explanation about repairing mitochondria is unverified speculation.

Read the original account
Negative account · personal report

Midday crashes during combined exposure

A 46-year-old woman described disappointing midday fatigue after about four weeks of MOTS-c while also using SLU-PP-332 and recently starting testosterone. A reply clarified that midday crashes predated these exposures.

Reported use in this account

Product
Product described as MOTS-c
Amount
5 mg
Frequency
Every five days, explicitly clarified in a reply
Route
Not specified clearly
Duration
In week four

Other exposures described: SLU-PP-332; Testosterone gel started about 20 days earlier; Exercise and caffeine; Midday fatigue already present before these exposures

The pre-existing symptom and several concurrent products prevent attribution. Product contents and any mitochondrial explanation were not verified.

Read the original account
Positive account · personal report

A modest energy lift during long workdays

A different commenter described a small pick-me-up during demanding workdays after about two weeks.

Reported use in this account

Product
Product described as MOTS-c
Amount
2 mg in the morning, with a reported additional 1–2 mg on some long workdays
Frequency
Morning use and occasional midday use; number of use days per week not stated
Route
Not specified clearly
Duration
About two weeks

Other exposures described: Fasted workouts; Long workdays

Workload, exercise, other exposures and product contents were not controlled; there were no energy measurements.

Read the original account

Approval status

No MOTS-c drug product is FDA approved. FDA's current compounding safety summary states that it has not identified human exposure data for drug products containing MOTS-c.

Native MOTS-c remains preclinical as a treatment

Most treatment claims rely on animal or laboratory work. A related CB4211 analog reached Phase 1, but that analog is not interchangeable with native MOTS-c.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether administered MOTS-c produces any meaningful human metabolic or performance benefit
  • Short- and long-term human safety
  • How synthetic products compare with the naturally produced peptide
  • Whether animal longevity or exercise findings translate to people

Summary

MOTS-c has preclinical metabolic and exercise findings. Controlled human outcome evidence remains missing.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.

  2. pubmedMOTS-c metabolism and insulin-sensitivity study

    Preclinical study in animal models; it does not establish a human treatment effect.

  3. pubmedHuman exercise study of mitochondrial-derived peptides

    Study of naturally circulating peptide levels after exercise, not administration as a therapy.

  4. clinical trialsClinicalTrials.gov: CB4211 Phase 1 study

    Completed early trial of a MOTS-c analog; the registry does not show public results and the analog is not native MOTS-c.

How we assess sources · Suggest a correction